2021
DOI: 10.1007/s13555-021-00627-4
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months

Abstract: Introduction: Real-world data comparing effectiveness of ixekizumab (IXE) and secukinumab (SEC) among biologic-experienced patients are limited. This study compared treatment patterns over 18 months among biologic-experienced patients with psoriasis receiving IXE or SEC in the USA. Methods: A retrospective observational study using administrative claims data from IBM Ò Watson Health MarketScan Ò Research Databases included adult patients with C 1 inpatient or C 2 non-diagnostic (C 30 days apart) outpatient cla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 28 publications
0
2
0
Order By: Relevance
“…After adjusting for both ICER discounts and adherence, differences in mean index drug costs PPPM between IXE and SEC users declined from US$596 (US$3990 vs US$3394) to US$28 (US$3794 vs US$3766). This highlights the added benefits of higher treatment adherence among IXE users as both treatments are equally expensive and no significant differences in ICER-adjusted all-cause and psoriasis-related costs between IXE and SEC were observed [ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…After adjusting for both ICER discounts and adherence, differences in mean index drug costs PPPM between IXE and SEC users declined from US$596 (US$3990 vs US$3394) to US$28 (US$3794 vs US$3766). This highlights the added benefits of higher treatment adherence among IXE users as both treatments are equally expensive and no significant differences in ICER-adjusted all-cause and psoriasis-related costs between IXE and SEC were observed [ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…Ixekizumab, an IL-17A inhibitor, has demonstrated efficacy and safety in the UNCOVER phase III trials [ 14 17 ] and a real-world Canadian study [ 18 ]. Moreover, ixekizumab has shown similar [ 12 ] or better adherence (i.e., the degree or extent to which a patient complies with the prescribed interval, and dose of a dosing regimen [ 19 ]) and persistence (i.e., time from initiation to discontinuation of therapy [ 19 ]), and lower risk of discontinuation compared with other biologics [ 20 23 ]. Although ixekizumab has been approved for use in Canada in adult patients with moderate-to-severe PsO since 2016 [ 24 ], data from real-world Canadian studies on ixekizumab-treated patients with PsO are still limited.…”
Section: Introductionmentioning
confidence: 99%